Phathom Pharmaceuticals Reports Tomorrow With Analysts Expecting the First Profitable Quarter Ever

Phathom Pharmaceuticals (NASDAQ: PHAT) reports second-quarter 2026 earnings before market open on July 30, 2026, with analysts expecting the company to narrow losses significantly as its VOQUEZNA franchise gains commercial traction. The central question is whether the biopharmaceutical company can sustain the momentum that has driven four consecutive quarters of earnings beats while demonstrating a clear path toward profitability. With analyst sentiment strongly bullish and price targets implying substantial upside, this report will test whether Phathom's gastrointestinal disease treatments are translating into sustainable revenue growth.

Part 1: Earnings Preview

Phathom Pharmaceuticals is a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, primarily through its VOQUEZNA franchise—a first-in-class potassium-competitive acid blocker (PCAB) for treating GERD and H. pylori infections. The company markets VOQUEZNA tablets for heartburn relief and erosive GERD, along with VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori treatment in adults.

Phathom is scheduled to report Q2 2026 results before market open on Thursday, July 30, 2026, with a conference call at 8:00 AM EDT. The consensus estimate calls for an EPS loss of $0.15 per share on revenue of $73.45 million. The company most recently reported Q1 2026 EPS of -$0.25, which beat estimates of -$0.27 by 7.41%.

Comparing to the same quarter last year, the expected Q2 2026 loss of $0.15 represents dramatic improvement from Q2 2025's reported loss of -$0.90 per share—an 83.33% reduction in losses year-over-year. This substantial narrowing of losses reflects the commercial ramp of VOQUEZNA products since their launch.

Three key themes define this earnings story:

Commercial Execution and Revenue Trajectory: Investors will scrutinize whether VOQUEZNA's revenue growth can sustain the acceleration seen in recent quarters. The company has posted sequential revenue increases from $28.5 million in Q1 2025 to $58.3 million in Q1 2026, and the $73.45 million estimate for Q2 2026 would represent another significant step-up. Market penetration in the competitive GERD treatment space and physician adoption rates will be critical metrics.

Path to Profitability: With consensus estimates projecting positive EPS of $0.02 for Q3 2026 and $1.56 for full-year 2027, this quarter's results will provide crucial evidence of whether Phathom can achieve profitability on its current trajectory. Operating leverage, gross margins, and the pace of operating expense growth relative to revenue will be key indicators.

Pipeline Development and Label Expansion: Beyond the current VOQUEZNA indications, investors are watching for updates on potential label expansions into eosinophilic esophagitis and adolescent populations, which could significantly expand the addressable market. Any clinical trial progress or regulatory milestones would provide additional growth catalysts.

Analyst commentary ahead of the release is notably bullish. HC Wainwright reiterated a "buy" rating with a $26 price target, while Barclays upgraded the stock from "equal weight" to "overweight" in March, raising their target from $16 to $18. The analyst community appears confident in the commercial trajectory, with the consensus "Moderate Buy" rating reflecting optimism about the company's ability to execute on its growth strategy while managing the transition toward profitability.

Part 2: Historical Earnings Performance

Phathom has established a consistent pattern of beating earnings estimates over the past four quarters, demonstrating improving operational execution as the VOQUEZNA franchise scales commercially.

In Q2 2025 (four quarters ago), the company reported a loss of -$0.90 per share versus estimates of -$0.86, missing by 4.65%—the only miss in the recent sequence. However, performance improved markedly thereafter. Q3 2025 delivered a 30% beat with a loss of -$0.28 versus -$0.40 expected, followed by Q4 2025's 20% beat at -$0.16 versus -$0.20 estimated. Most recently, Q1 2026 posted a 7.41% beat with -$0.25 versus -$0.27 consensus.

The trend is unmistakable: losses are narrowing substantially quarter-over-quarter, from -$0.90 four quarters ago to -$0.25 last quarter—a 72% reduction in the magnitude of losses. The beat percentages have moderated from the dramatic 30% surprise in Q3 2025 to more modest single-digit beats recently, suggesting that analyst estimates are catching up to the company's improving fundamentals. This pattern of consistent beats combined with rapidly narrowing losses indicates strong commercial execution and operating leverage as VOQUEZNA revenue scales.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Phathom typically reports earnings before market open, meaning Day 0 represents the first trading session where the market reacts to results, while Day +1 captures follow-through momentum.

Historical price behavior shows significant volatility around earnings releases, with an average absolute Day 0 move of 7.63% and Day +1 move of 7.62%—indicating that initial reactions are often sustained into the following session. The Day 0 range averages 16.71%, reflecting substantial intraday volatility as investors digest results.

The most recent earnings on April 30, 2026 saw a 4.92% decline on Day 0 despite the earnings beat, followed by a 7.23% rally on Day +1—suggesting initial profit-taking gave way to recognition of the positive fundamentals. Prior to that, February 2026 earnings triggered a 10.06% Day 0 surge that partially reversed with a 7.37% Day +1 decline. The pattern is inconsistent in direction but consistently large in magnitude, with moves frequently exceeding 10% in either direction. Notably, the May 2025 report produced the most dramatic reaction: a 21.68% Day 0 plunge followed by further 17.86% Day +1 decline, demonstrating the stock's sensitivity to any disappointments during the critical commercial launch phase.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 19.42% for the upcoming earnings release, which is substantially higher than the historical average Day 0 move of 7.63%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction, possibly reflecting heightened uncertainty about the sustainability of the revenue ramp or the path to profitability. The 19.42% expected move also exceeds the average Day 0 range of 16.71%, indicating the market is pricing in potential for an outsized move in either direction.

Part 3: What Analysts Are Saying

Analyst sentiment on Phathom Pharmaceuticals is strongly bullish, with a consensus rating of 4.55 out of 5.0 (between Buy and Strong Buy) and an average price target of $23.70—implying 104% upside from the current price of $11.64.

The rating breakdown shows overwhelming buy-side conviction: 8 Strong Buy ratings, 1 Moderate Buy, and 2 Hold ratings, with zero sell recommendations among the 11 analysts covering the stock. This lopsided distribution reflects confidence in the VOQUEZNA commercial trajectory and the company's path toward profitability.

Analyst sentiment has remained unchanged over the past month, maintaining the strong bullish stance. The price target range spans from a low of $13.00 to a high of $29.00, with even the most conservative target implying 12% upside. The wide range reflects differing assumptions about the pace of commercial adoption and timeline to profitability, but the consensus clearly favors significant appreciation potential as the company executes on its growth strategy.

Part 4: Technical Picture

Phathom's technical setup heading into earnings shows mixed signals with recent improvement. The Barchart Technical Opinion currently registers a Sell signal at 8%, representing a significant strengthening from last week's Sell at 24% and a dramatic reversal from last month's Sell at 88%. This rapid improvement in the technical score suggests building positive momentum despite the bearish label.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive reading indicates near-term momentum has shifted favorably, supporting the recent technical improvement
• Medium-term (50% Sell): Neutral-to-negative signal suggests consolidation or mild weakness in the intermediate timeframe
• Long-term (50% Sell): Neutral-to-negative reading reflects ongoing challenges in establishing a sustained uptrend over longer periods

Trend Characteristics: The trend is characterized by Minimum strength and the Weakest direction, indicating the stock lacks conviction in either direction and remains vulnerable to volatility around the earnings catalyst.

The stock is currently trading at $11.64, positioned above the 10-day ($11.38), 20-day ($11.41), 50-day ($10.90), and 100-day ($11.29) moving averages, but below both the 5-day ($11.66) and critical 200-day ($12.69) moving averages.

The technical picture presents a cautiously constructive setup for earnings. While the stock has reclaimed support above key short- and intermediate-term moving averages, the failure to break above the 200-day moving average at $12.69 represents a significant resistance level that has capped upside momentum. The 52-week range of $7.84 to $18.31 shows the stock is trading in the lower half of its annual range, providing room for upside if results exceed expectations. However, the weak trend characteristics and mixed timeframe signals suggest the stock remains technically vulnerable to disappointment. The rapid improvement in the Barchart Opinion score from 88% Sell a month ago to just 8% Sell today indicates building positive momentum, but the lack of conviction in the trend means earnings will likely be the decisive catalyst that determines whether the stock can break through resistance or retest support levels.